Home » Topics » BioWorld Science

BioWorld Science
RSS

Interim phase II data for darolutamide demonstrate efficacy in advanced AR-positive TNBC

Dec. 17, 2020

Heat Biologics completes ZVX-60 gp96-based COVID-19 vaccine cell line

Dec. 17, 2020

Molecular Partners advances pipeline

Dec. 17, 2020

New phase III trial evaluates siltuximab for COVID-19 or viral-associated ARDS

Dec. 17, 2020

FDA approves Margenza for pretreated metastatic HER2-positive breast cancer

Dec. 17, 2020

Through mTOR, ketamine affects protein translation hub

Dec. 17, 2020

Phase I data presented for cannabidivarin for treating epilepsy in patients with Rett syndrome

Dec. 17, 2020

FDA places partial clinical hold on odronextamab lymphoma trials

Dec. 17, 2020

Abpro initiates phase II/III registrational studies of ABP-300 as treatment of COVID-19

Dec. 17, 2020

First subjects dosed in phase I study of PN-235

Dec. 17, 2020

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...